NASDAQ:ACRS - Aclaris Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $5.33 +0.05 (+0.95 %) (As of 05/22/2019 05:31 AM ET)Previous Close$5.28Today's Range$5.26 - $5.5752-Week Range$5.04 - $21.97Volume562,600 shsAverage Volume522,002 shsMarket Capitalization$219.98 millionP/E RatioN/ADividend YieldN/ABeta1.24 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Aclaris Therapeutics, Inc., a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies for dermatological and immuno-inflammatory diseases in the United States. It operates in two segments, Dermatology Therapeutics and Contract Research. The company offers ESKATA, a formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor; and RHOFADE, an oxymetazoline hydrochloride cream. It is also developing A-101, a high-concentration formulation of hydrogen peroxide that is in Phase III clinical trial for common warts; and ATI-501 and ATI-502 Janus kinase (JAK) inhibitors, which are in Phase II clinical trials for alopecia areata (AA) and other dermatological indications. In addition, the company's products under development include ATI-450 MK-2 pathway oral inhibitor for the treatment of rheumatoid arthritis, psoriasis, hidradenitis suppurativa, cryopyrin-associated periodic syndrome, and pyoderma gangrenosum; ATI-1777 JAK1/JAK3 soft topical inhibitor for atopic dermatitis, vitiligo, and alopecia areata; ITK/JAK3 soft topical and oral inhibitors to treat psoriasis and inflammatory diseases; MK-2 pathway oral inhibitor for oncology; and ITK-JAK3 oral gut-restricted inhibitor for ulcerative colitis/Crohn's disease. Further, it provides contract research laboratory services. Aclaris Therapeutics, Inc. has a license and collaboration agreement with Rigel Pharmaceuticals, Inc. for the development and commercialization of JAK inhibitors. The company was founded in 2012 and is headquartered in Wayne, Pennsylvania. Receive ACRS News and Ratings via Email Sign-up to receive the latest news and ratings for ACRS and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ACRS Previous Symbol CUSIPN/A CIK1557746 Webhttp://www.aclaristx.com/ Phone484-324-7933Debt Debt-to-Equity Ratio0.16 Current Ratio4.33 Quick Ratio4.30Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$10.09 million Price / Sales21.80 Cash FlowN/A Price / Cash FlowN/A Book Value$4.42 per share Price / Book1.21Profitability EPS (Most Recent Fiscal Year)($4.03) Net Income$-132,740,000.00 Net Margins-999.53% Return on Equity-78.05% Return on Assets-61.79%Miscellaneous Employees169 Outstanding Shares41,272,000Market Cap$219.98 million Next Earnings Date8/2/2019 (Estimated) OptionableOptionable Aclaris Therapeutics (NASDAQ:ACRS) Frequently Asked Questions What is Aclaris Therapeutics' stock symbol? Aclaris Therapeutics trades on the NASDAQ under the ticker symbol "ACRS." How were Aclaris Therapeutics' earnings last quarter? Aclaris Therapeutics Inc (NASDAQ:ACRS) issued its quarterly earnings results on Wednesday, May, 8th. The biotechnology company reported ($0.91) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.86) by $0.05. The biotechnology company had revenue of $5.04 million for the quarter, compared to analyst estimates of $5.13 million. Aclaris Therapeutics had a negative net margin of 999.53% and a negative return on equity of 78.05%. View Aclaris Therapeutics' Earnings History. When is Aclaris Therapeutics' next earnings date? Aclaris Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, August 2nd 2019. View Earnings Estimates for Aclaris Therapeutics. What price target have analysts set for ACRS? 4 Wall Street analysts have issued 12 month price targets for Aclaris Therapeutics' shares. Their forecasts range from $13.00 to $50.00. On average, they anticipate Aclaris Therapeutics' share price to reach $32.3333 in the next twelve months. This suggests a possible upside of 506.6% from the stock's current price. View Analyst Price Targets for Aclaris Therapeutics. What is the consensus analysts' recommendation for Aclaris Therapeutics? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aclaris Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aclaris Therapeutics. What are Wall Street analysts saying about Aclaris Therapeutics stock? Here are some recent quotes from research analysts about Aclaris Therapeutics stock: 1. According to Zacks Investment Research, "Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists of A-101, a high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis a common non-malignant skin tumor and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts which are in different clinical trial. Aclaris Therapeutics, Inc. is headquartered in Malvern, Pennsylvania. " (5/21/2019) 2. Cantor Fitzgerald analysts commented, "We expect upwards earnings revisions to levels not reflected in sell-side consensus expectations to drive shares higher. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $50." (3/22/2019) Has Aclaris Therapeutics been receiving favorable news coverage? News articles about ACRS stock have trended neutral on Wednesday, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Aclaris Therapeutics earned a daily sentiment score of 0.2 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the next several days. Who are some of Aclaris Therapeutics' key competitors? Some companies that are related to Aclaris Therapeutics include Axovant Sciences (AXON), Spectrum Pharmaceuticals (SPPI), Wave Life Sciences (WVE), Clovis Oncology (CLVS), Myovant Sciences (MYOV), Rocket Pharmaceuticals (RCKT), G1 Therapeutics (GTHX), Deciphera Pharmaceuticals (DCPH), CymaBay Therapeutics (CBAY), ANI Pharmaceuticals (ANIP), Dicerna Pharmaceuticals (DRNA), Kiniksa Pharmaceuticals (KNSA), Vanda Pharmaceuticals (VNDA), TherapeuticsMD (TXMD) and CannTrust (CNTTF). What other stocks do shareholders of Aclaris Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aclaris Therapeutics investors own include Corbus Pharmaceuticals (CRBP), Ocular Therapeutix (OCUL), TherapeuticsMD (TXMD), Inovio Pharmaceuticals (INO), Zynerba Pharmaceuticals (ZYNE), Crispr Therapeutics (CRSP), Exelixis (EXEL), Amicus Therapeutics (FOLD), Progenics Pharmaceuticals (PGNX) and Sorrento Therapeutics (SRNE). Who are Aclaris Therapeutics' key executives? Aclaris Therapeutics' management team includes the folowing people: Dr. Neal S. Walker D.O., Co-Founder, CEO, Pres & Director (Age 49)Mr. Christopher V. Powala, Co-Founder and Chief Regulatory & Devel. Officer (Age 60)Dr. Stuart D. Shanler, Co-Founder & Chief Scientific Officer (Age 58)Mr. Frank Ruffo, Co-Founder & CFO (Age 53)Ms. Kamil Ali-Jackson J.D., Co-Founder, Chief Legal Officer, Chief Compliance Officer & Sec. (Age 60) Who are Aclaris Therapeutics' major shareholders? Aclaris Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.59%), Broadfin Capital LLC (4.92%), Man Group plc (2.87%), FMR LLC (2.59%), Dimensional Fund Advisors LP (1.82%) and Rice Hall James & Associates LLC (1.69%). Company insiders that own Aclaris Therapeutics stock include Anand Mehra, Andrew Kenneth William Powell, Andrew N Schiff, Frank Ruffo, James E Flynn, Kamil Ali-Jackson, Neal Walker and Stephen A Tullman. View Institutional Ownership Trends for Aclaris Therapeutics. Which institutional investors are selling Aclaris Therapeutics stock? ACRS stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, BlackRock Inc., Parametric Portfolio Associates LLC, Charles Schwab Investment Management Inc., HighTower Advisors LLC, Jefferies Group LLC, Northern Trust Corp and Blair William & Co. IL. Company insiders that have sold Aclaris Therapeutics company stock in the last year include James E Flynn and Kamil Ali-Jackson. View Insider Buying and Selling for Aclaris Therapeutics. Which institutional investors are buying Aclaris Therapeutics stock? ACRS stock was acquired by a variety of institutional investors in the last quarter, including Man Group plc, Renaissance Technologies LLC, Dimensional Fund Advisors LP, Rice Hall James & Associates LLC, Broadfin Capital LLC, Tibra Equities Europe Ltd, Geode Capital Management LLC and JPMorgan Chase & Co.. Company insiders that have bought Aclaris Therapeutics stock in the last two years include Anand Mehra, Andrew Kenneth William Powell, Andrew N Schiff, Frank Ruffo, Neal Walker and Stephen A Tullman. View Insider Buying and Selling for Aclaris Therapeutics. How do I buy shares of Aclaris Therapeutics? Shares of ACRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Aclaris Therapeutics' stock price today? One share of ACRS stock can currently be purchased for approximately $5.33. How big of a company is Aclaris Therapeutics? Aclaris Therapeutics has a market capitalization of $219.98 million and generates $10.09 million in revenue each year. The biotechnology company earns $-132,740,000.00 in net income (profit) each year or ($4.03) on an earnings per share basis. Aclaris Therapeutics employs 169 workers across the globe. What is Aclaris Therapeutics' official website? The official website for Aclaris Therapeutics is http://www.aclaristx.com/. How can I contact Aclaris Therapeutics? Aclaris Therapeutics' mailing address is 640 LEE ROAD SUITE 200, WAYNE PA, 19087. The biotechnology company can be reached via phone at 484-324-7933 or via email at [email protected] MarketBeat Community Rating for Aclaris Therapeutics (NASDAQ ACRS)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 252 (Vote Outperform)Underperform Votes: 223 (Vote Underperform)Total Votes: 475MarketBeat's community ratings are surveys of what our community members think about Aclaris Therapeutics and other stocks. Vote "Outperform" if you believe ACRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACRS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/22/2019 by MarketBeat.com StaffFeatured Article: Why does a company issue an IPO? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.